Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERF2 | Q15554 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23736377 | 0.90 | — | — | |
| SCHEMBL15726434 | 0.87 | PDE4B (0.35) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23736111 | 0.79 | SLC6A2 (0.32) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16003117 | 0.75 | SLC6A2 (0.33) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14234456 | 0.74 | GAA (0.33) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17282907 | 0.74 | GAA (0.33) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14234967 | 0.74 | GAA (0.33) | ALDH1A1GAASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23736118 | 0.74 | PDE4B (0.33) | ALDH1A1GAA | |
| SCHEMBL15727251 | 0.71 | CTSD (0.33) | TERF2 | |
| SCHEMBL14235320 | 0.69 | RXRA (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | TERF2 3508/4885ALDH1A1 2364/4885GAA 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.